Reblozyl — Total Revenues
Bristol-Myers Squibb Reblozyl — Total Revenues increased by 8.3% to $615.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 37.6%, from $447.00M to $615.00M. Over 3 years (FY 2021 to FY 2024), Reblozyl — Total Revenues shows an upward trend with a 47.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration, successful clinical adoption, or expanded patient access, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Reblozyl, a therapeutic produc...
Peer comparison
Comparable to revenue metrics for specialized biologic or oncology products at other large-cap pharmaceutical companies, often evaluated against consensus growth estimates for high-value therapeutic assets.
bmy_segment_reblozyl_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $128.00M | $160.00M | $151.00M | $156.00M | $172.00M | $190.00M | $199.00M | $206.00M | $234.00M | $248.00M | $320.00M | $354.00M | $425.00M | $447.00M | $547.00M | $478.00M | $568.00M | $615.00M |
| QoQ Change | — | +25.0% | -5.6% | +3.3% | +10.3% | +10.5% | +4.7% | +3.5% | +13.6% | +6.0% | +29.0% | +10.6% | +20.1% | +5.2% | +22.4% | -12.6% | +18.8% | +8.3% |
| YoY Change | — | — | — | — | +34.4% | +18.8% | +31.8% | +32.1% | +36.0% | +30.5% | +60.8% | +71.8% | +81.6% | +80.2% | +70.9% | +35.0% | +33.6% | +37.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's reblozyl — total revenues?
- Bristol-Myers Squibb (BMY) reported reblozyl — total revenues of $615.00M in Q3 2025.
- How has Bristol-Myers Squibb's reblozyl — total revenues changed year-over-year?
- Bristol-Myers Squibb's reblozyl — total revenues increased by 37.6% year-over-year, from $447.00M to $615.00M.
- What is the long-term trend for Bristol-Myers Squibb's reblozyl — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's reblozyl — total revenues has grown at a 47.6% compound annual growth rate (CAGR), from $551.00M to $1.77B.
- What does reblozyl — total revenues mean?
- The total revenue generated from sales of the drug Reblozyl.